Acoramidis Hydrochloride

CHEMBL4650226 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
328.8 g/mol
LogP
Phase
4

The hydrochloride salt formulation of acoramidis, a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy. It works identically to acoramidis, binding to the transthyretin protein and preventing it from dissociating into the misfolded fragments that accumulate as amyloid in cardiac tissue. Consistent three-times-daily dosing is important to maintain adequate drug levels for effective protein stabilization.

분자량

328.7600 g/mol

TPSA

75.20 Ų

작용 기전

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F.Cl

InChI

InChI=1S/C15H17FN2O3.ClH/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16;/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20);1H

Molecular Formula

C15H18ClFN2O3

HBD / HBA

3 / 5

회전 가능 결합

6

무거운 원자

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

The hydrochloride salt formulation of acoramidis, a transthyretin stabilizer used to treat transthyretin amyloid cardiomyopathy. It works identically to acoramidis, binding to the transthyretin protein and preventing it from dissociating into the misfolded fragments that accumulate as amyloid in cardiac tissue. Consistent three-times-daily dosing is important to maintain adequate drug levels for effective protein stabilization.

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

Yes, Acoramidis Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650226. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135307127. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.